Published: 1 May 2019
Author(s): Roy Beigel, Israel Mazin, Orly Goitein, Romana Herscovici, Sharon Natanzon, Fernando Chernomordik, Sagit Ben-Zekry, Paul Fefer, Avishay Grupper, Shlomi Matetzky
Issue: May 2019
Section: Original Article

Intermediate-risk pulmonary embolism (PE) patients present a therapeutic dilemma. While some are at risk for developing adverse events, possibly requiring escalation therapy, most will have a benign course. Our aim was to define predictors which will identify those patients who will not deteriorate despite the presence of RV involvement.


Stay informed on our latest news!